Novartis, AG v. HEC Pharm Co., Ltd. et al.
Infringement action filed 18 Jan 2023 in the U.S. Supreme Court and closed 17 Apr 2023, with US9187405B2 asserted. Recorded basis of termination: petition dismissed.
Case record
- Patent involved
- US9187405B2
- Case no.
- 22-671
- Verdict cause
- Infringement action
- Court
- U.S. Supreme Court
- Court level
- Supreme Court
- Case region
- District of Columbia
- Chief judge
- None recorded
- Trial level
- Judicial review
- Filed – Closed
- 18 Jan 2023 – 17 Apr 2023
- Duration
- 89 days
- Basis of termination
- Petition Dismissed
- Products & marks
- S1P receptor modulators for treating relasping-remitting multiple sclerosis
- Validity challenges
- None recorded
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
US9187405B2
- Legal status
- None recorded
- Validity challenges
- None recorded
- Licences recorded
- None recorded
Parties of record
Novartis, AG
- Core tech
- Not recorded
- Counsel
- Deanne Elizabeth Maynard
- Firm
- Morrison & Foerster, LLP
HEC Pharm Co., Ltd.
- Core tech
- Not recorded
- Counsel
- Peter K. Stris
- Firm
- Stris & Maher LLP
- Also named
- HEC Pharm USA, Inc.
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Deanne Elizabeth Maynard | Novartis, AG | Plaintiff |
| Peter K. Stris | HEC Pharm Co., Ltd. | Defendant |
Basis of termination
From the record · verbatim“Petition DENIED”
Case 22-671 · U.S. Supreme Court · closed 17 April 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 22-671?
22-671 is a patent infringement action brought by Novartis, AG against HEC Pharm Co., Ltd., filed on 18 Jan 2023 in the U.S. Supreme Court. The case closed on 17 April 2023.
Which patent was asserted in 22-671?
US9187405B2. The record also lists S1P receptor modulators for treating relasping-remitting multiple sclerosis.
How was case 22-671 terminated?
The recorded basis of termination is petition dismissed. The termination text reads: “Petition DENIED”
How long did case 22-671 take?
89 calendar days, from filing on 18 Jan 2023 to closure on 17 April 2023.
Who were the attorneys and the judge in 22-671?
Deanne Elizabeth Maynard is recorded as counsel for plaintiff Novartis. Peter K. Stris appears for defendant HEC Pharm.
Disclaimer. This page reproduces publicly available court docket data for case 22-671 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.